Original from: Guardant Health

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a strategic collaboration with Pfizer, Inc. (NYSE: PFE), to support the development and commercialization of Pfizer’s oncology portfolio using the Guardant Infinity™ smart liquid biopsy platform.

Under the multi-year collaboration agreement, Guardant and Pfizer aim to:

· Utilize Guardant’s portfolio of liquid biopsy tests in Pfizer’s global clinical studies

· Evaluate the clinical utility of (a) circulating tumor DNA (ctDNA) level as a surrogate endpoint to monitor therapy response and (b) related blood-based epigenomic analyses

The collaboration will also provide Pfizer with access to Guardant’s liquid biopsy tests in China for their global clinical trials that include China cohorts. In July 2022, Guardant announced a strategic partnership with Adicon Holdings Limited, a leading independent clinical laboratory company based in China, to offer Guardant tests to biopharmaceutical companies conducting clinical trials in China. Cancer is the leading cause of death in China, with over three million cancer-related deaths in 2020.

Source: Guardant Health Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform